BlackRock, Inc. filed Amendment No. 2 to a Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 5,206,581 shares of Enliven Therapeutics Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficial ownership of 5,206,581 shares of Enliven Therapeutics Inc. common stock.
  • Percent of class: The reported stake represents 7.1% of the outstanding common shares.
  • Sole voting power: BlackRock disclosed sole power to vote or direct the vote of 5,097,086 shares.
  • Sole dispositive power: BlackRock disclosed sole power to dispose or direct the disposition of 5,206,581 shares.
  • Shared voting and dispositive power: Both shared voting power and shared dispositive power are reported as 0.
  • Date of event: The triggering event date is reported as September 30, 2026.

BlackRock's Schedule 13G Amendment on Enliven Therapeutics Common Stock

According to the filing, BlackRock, Inc., organized in Delaware and headquartered at 50 Hudson Yards, New York, NY 10001, submitted Amendment No. 2 to a Schedule 13G covering its holdings in Enliven Therapeutics Inc. (CUSIP 29337E102), whose principal executive offices are located at 205 Park Road, Burlingame, CA 94010. The filing identifies BlackRock as a parent holding company (type "HC") and states that the disclosure reflects securities beneficially owned, or deemed to be beneficially owned, by certain business units of BlackRock, Inc. and its subsidiaries and affiliates, referred to in the filing as the "Reporting Business Units."

The filing states that various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the common stock of Enliven Therapeutics Inc. The filing further states that "no one person's interest in the common stock of ENLIVEN THERAPEUTICS INC is more than five percent of the total outstanding common shares." Item 7 of the filing directs readers to Exhibit 99 for the identity and classification of the relevant subsidiary that acquired the securities being reported on by BlackRock as parent holding company.

The filing was signed by Spencer Fleming, identified as Managing Director of BlackRock, Inc., and dated October 27, 2026. The certification included states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

BlackRock, Inc. filed Amendment No. 2 to a Schedule 13G reporting beneficial ownership of 5,206,581 shares, or 7.1%, of Enliven Therapeutics Inc. common stock as of September 30, 2026, with sole voting power over 5,097,086 shares and sole dispositive power over all 5,206,581 shares.